Atrial Fibrillation: Rate vs Rhythm Control in 2026 — EAST-AFNET 4 and Beyond
The Paradigm Shift: EAST-AFNET 4 Results
The EAST-AFNET 4 trial enrolled 2,789 patients with early atrial fibrillation (diagnosed within 12 months) and randomized them to early rhythm control versus usual care. Early rhythm control reduced the primary composite of cardiovascular death, stroke, and hospitalization for heart failure or acute coronary syndrome by 21% (HR 0.79, 96% CI 0.66-0.94, p=0.005). The benefit emerged within the first year and persisted through a median follow-up of 5.1 years, fundamentally challenging the equipoise established by AFFIRM and RACE.
Critically, the safety signal that plagued earlier rhythm control trials was absent. The EAST-AFNET 4 cohort had lower rates of serious adverse events in the rhythm control arm, largely attributable to improved antiarrhythmic drug selection and greater use of catheter ablation compared to historical trials.
DOAC Selection: Practical Considerations
All four DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) demonstrate non-inferior or superior efficacy compared to warfarin for stroke prevention in non-valvular AF. The ARISTOPHANES study and multiple real-world analyses suggest apixaban may have the most favorable bleeding profile (major bleeding rate 2.1% vs 3.6% for warfarin per year). For patients with CrCl 15-25 mL/min, apixaban 2.5 mg BID remains the only DOAC with adequate safety data. Dabigatran is the sole DOAC with a specific reversal agent (idarucizumab), while andexanet alfa covers factor Xa inhibitors.
Catheter Ablation Outcomes: CABANA and CASTLE-AF
The CABANA trial showed ablation reduced the primary endpoint by 14% in intention-to-treat analysis (HR 0.86, 95% CI 0.65-1.15), but per-protocol analysis favoring ablation reached significance (HR 0.73, p=0.006). CASTLE-AF demonstrated a striking 38% reduction in all-cause mortality with ablation in patients with AF and heart failure (LVEF ≤35%). The RAFT-AF trial confirmed ablation superiority to amiodarone for AF in heart failure, with a 5.4% absolute improvement in LVEF at 24 months.
Sponsored
Antiarrhythmic Drug Selection in 2026
For patients without structural heart disease, flecainide (100-150 mg BID) and propafenone (225-300 mg BID) remain first-line. In patients with coronary artery disease or LVH, dronedarone (400 mg BID) offers rhythm control with a favorable safety profile (ATHENA trial: 24% reduction in cardiovascular hospitalization or death). Sotalol requires QTc monitoring and is best avoided with eGFR below 40 mL/min. Amiodarone remains most effective (65-70% sinus rhythm maintenance at 1 year) but carries cumulative organ toxicity requiring thyroid, pulmonary, hepatic, and ophthalmologic surveillance.
Clinical Decision Framework
Current 2023 ACC/AHA/ACCP/HRS guidelines recommend early rhythm control for symptomatic AF, AF with heart failure, and AF diagnosed within 12 months. Anticoagulation decisions should be guided by CHA2DS2-VASc score (threshold ≥2 in men, ≥3 in women), independent of rhythm strategy. The key takeaway from EAST-AFNET 4 is temporal: rhythm control initiated early after AF diagnosis confers benefit, while the same strategy applied years later may not replicate these outcomes.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.